Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Global Continuous Glucose Monitoring Systems Market by Components (Sensors, Transmitters & Receivers, and Integrated Insulin Pumps), Demographics (Child Population (<14 years), and Adult Population (>14 years)), and End Users (Diagnostic Centers/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

LI_161795
Pages: 203
Dec 2016 | 9500 Views
face gplus_n
Author's : Pallavi Jaiswal
Tables: 58
Charts: 58
twit_n pr_n

Continuous Glucose Monitoring Systems Market Overview:

The global CGMS market $589 million in 2015, and is projected to reach $6,238 million by 2022, registering a CAGR of approximately 39.9% from 2016 to 2022. Real-time continuous glucose monitoring is of utmost importance across all age groups to manage diabetes effectively. Continuous glucose monitoring system (CGMS) enables effective managing of blood glucose levels by providing trend data as well as alarms for the fluctuations in glucose levels.

Global Continuous Glucose Monitoring Systems Market

Diabetes, a chronic lifestyle disease, is classified into type 1 and type 2 diabetes. In type 1 diabetes, the pancreas is unable to produce sufficient or requisite amount of insulin hormone, which is required for the breakdown of glucose. It is prevalent in children or young adults and as per the global estimates of International Diabetes Federation (IDF), in 2015, Type 1 diabetes has affected around 542,100 children in the age group below 15 years. Whereas, in type 2 diabetes, the pancreas produce insulin, but the cells do not respond and/or lack the ability to uptake the insulin available in the blood stream. It is the most prevalent type of diabetes, affecting around 8% share of the global population in the age group of 2079 years, which accounts for more than 95% of all types of diabetes.

About 19% of the global healthcare expenditure on diabetes was spent on low- and middle-income groups, which comprise a significant proportion of diabetic patients. On an average, about $5,374 - $9,641 per person was spent by individuals belonging to high-income countries, whereas about $401 - $688 was spent in low- and middle-income countries. It is observed that the U.S. spent about $320 billion of its health budgets for diabetes management, whereas China, with the most number of diabetes population spent about $51 billion on diabetes. The combined healthcare cost of three leading countries, namely U.S., Germany, and China with respect to the prevalence of diabetes is almost 60% of the global healthcare expenditure on diabetes. It can be inferred that people living in low- and middle-income countries spend more on diabetes management as compared to the high-income groups. This disparity in diabetes healthcare expenditure among high, low, and middle-income countries is due to lack of access to health insurance and government-provided medical services.

Furthermore, according to some reports and healthcare experts, about 193 million people, or close to half (46%) of all people with diabetes are undiagnosed, which has led to adverse and costly implications. Thus, it is evident that diabetes management is imperative across all geographical regions and in the age group of 50-79 years. Measuring/monitoring and managing glucose levels are primary tasks in diabetes management, which can be conducted using glucose monitoring devices. CGMS market is mainly driven by enhanced technological innovations, such as higher convenience offered by CGMS over self-monitoring blood glucose (SMBG) devices, and the detection of hypoglycemic and hyperglycemic events by CGMS. Increase in health awareness and affordability of devices in the developed and developing economies have contributed towards the market growth.

Global Continuous Glucose Monitoring Systems Market

The global continuous glucose monitoring (CGM) systems market is segmented based on component, end user segment, demographics, and geography. Based on the frequency of use, the CGM components market is sub segmented into sensors, transmitters & receivers, and integrated insulin pumps. Based on end user segment, the market is classified into diagnostics/clinics, ICUs, and home healthcare settings. Based on demographics, the market is divided into child population and adult population. Child population segment includes population in the age group of up to 14 years, whereas adult segment includes population in the age group of above 14years. By geography, this market is studied with respect to four major regions North America, Europe, Asia-Pacific, and LAMEA. The report includes the revenue generated from the sales of these aforementioned categories.

Global Continuous Glucose Monitoring Systems Market

The untapped regions such as Asia-Pacific, Africa, and Latin America are anticipated to emerge as a lucrative market, owing to the presence of large pool of diabetic patients, which makes them highly opportunistic markets for investment, and rise in disposable incomes. Moreover, in highly populous countries, about 80% to 90% of the people with diabetes remain undiagnosed, whereas it is only 30% in high-income countries. The aforementioned factors are expected to boost the growth of the CGMS market in the Asia-Pacific and LAMEA region.

The global CGMS market is still in the developing phase, with CGMS technology being the core sub-set in the value chain of diabetes monitoring devices. Therefore, product development is the key strategy adopted by market players, followed by collaboration. For instance, on September 2016, Abbott received FDA approval for Freestyle Libre Pro System. This system can provide patients ambulatory glucose profile to healthcare professionals.

Acquisition is another key strategy that has been adopted by key companies. Due to the presence of numerous small-sized to mid-sized companies, the larger companies acquire smaller and emergent companies to curb the competition and increase their revenue. For instance,on May 2, 2016, DexCom acquired Nintamed, a distributor company with presence in Switzerland, Germany, and Austria to improve the global access to CGM technologies.

The key players profiled in the report include Abbott Laboratories, Dexcom, Inc., Echo Therapeutics, Inc., GlySens Incorporated, Johnson & Johnson, Medtronic plc, Senseonics Holdings, Inc., and F. Hoffmann-La Roche Ltd. Other players in the CGMS market include (profiles not included in the report) include AgaMatrix, Inc., Arkray USA, Inc., Glucovation, GlySure, OrSense, GlySure, and Pinnacle Technology.

Key Benefits

  • The report provides an extensive analysis of the current trends and highlights the market potential from 2014 to 2022, in terms of value.
  • The market scenario is comprehensively analyzed with respect to the components, demographics, and end user.
  • Comprehensive analysis of the patents is provided to determine the prevailing opportunities.
  • Recent developments, key manufacturers, and market shares are listed in this report to analyze the competitive scenario of the market.
  • In-depth analysis of the market based on geography gives an understanding of the regional market, which assists in strategic business planning.

CGMS Market Key Segments:

The CGMS market is segmented based on component, end user segment, end user demographics, and geography (country-level analysis).

By Component

  • Sensors
  • Transmitters & Receivers
  • Integrated Insulin Pumps

By Demographics

  • Child Population (=14 years)
  • Adult Population (>14 years)

By End User

  • Diagnostics/Clinics
  • ICUs
  • Home Healthcare

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Norway
    • Sweden
    • Denmark
    • Finland
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Australia
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Venezuela
    • Argentina
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO Perspective

Chapter: 3 MARKET OVERVIEW

3.1. Market definition
3.2. Need for glucose monitoring systems

3.2.1. Diabetesa pandemic

3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. Global healthcare expenditure on diabetes

3.3. Technological Advancements IN CGMS

3.3.1.1. Smartphone-connected CGMS
3.3.1.2. Wearable and smartphone-connected CGMS
3.3.1.3. 'Smart diabetes management solutionbionic/artificial pancreas
3.3.1.4. Non-invasive CGMS
3.3.1.5. Invasive CGMS

3.3.2. CGMS: PRIME END USER SEGMENTS

3.3.2.1. CGMS: role in intensive care units (ICUs)

3.3.2.1.1. STRESS HYPERGLYCEMIA: COMMON OCCURRENCE IN ICUS

3.3.2.2. Non-standardization and erroneous glycemic control across ICUs
3.3.2.3. Benefits and driving factors of CGMS in ICUs

3.3.2.3.1. USE OF CGMS FOR TIGHT GLYCEMIC CONTROL IN ICUS
3.3.2.3.2. COST BENEFITS DUE TO USE OF CGMS
3.3.2.3.3. LOWER EFFECTIVENESS OF POC GLUCOMETERS THAN CGMS IN ICUS
3.3.2.3.4. CGMS: MOST PREFERRED BY ICU STAFF

3.4. Key Findings

3.4.1. Top investment pockets

3.4.1.1. CGMS market, by components

3.4.2. Top winning strategies

3.5. Value Chain Analysis
3.6. Patent Analysis

3.6.1. Patent analysis, by market participant
3.6.2. U.S. patent analysis, by market participant
3.6.3. Patent analysis, by year

3.7. Market Share Analysis, 2015
3.8. Government Regulations

3.8.1. FDA regulations (21CFR820)

3.8.1.1. Objective and Scope of FDA 21CFR820

3.8.2. ISO regulations (ISO 13485:2003)

3.8.2.1. Objective and Scope of ISO 13485:2003

3.9. Europe Reimbursement Scenario

3.9.1. Germany
3.9.2. France
3.9.3. UK
3.9.4. Spain
3.9.5. Italy

3.10. Market dynamics

3.10.1. Drivers

3.10.1.1. Benefits of CGMS over POC glucometers
3.10.1.2. Rise in incidence of diabetes cases
3.10.1.3. Technological advancements

3.10.2. Restraints

3.10.2.1. Adverse effects and accuracy
3.10.2.2. Reimbursement and stringent regulatory issues

3.10.3. Opportunities

3.10.3.1. High adoption rate of CGMS in home healthcare and ICUs
3.10.3.2. Increase in product awareness
3.10.3.3. High undiagnosed patient population

Chapter: 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT

4.1. Overview

4.1.1. Market size and forecast

4.2. Sensors

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.2.3.1. Non-invasive glucose sensors
4.2.3.2. Subcutaneous sensors (Minimally Invasive Sensors)
4.2.3.3. Conventional technologyHolter-type retrospective sensors
4.2.3.4. Advanced technologyReal-time sensors

4.3. Transmitters & Receivers

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. Integrated Insulin pumps

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKETBY DEMOGRAPHICS

5.1. Overview

5.1.1. Market size and forecast

5.2. Adult Population (>14 years)

5.2.1. Market size and forecast

5.3. Children Population (14 years)

5.3.1. Market size and forecast

Chapter: 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Diagnostic centers/clinics

6.2.1. Market size and forecast
6.2.2. Reimbursement scenario

6.3. ICUs

6.3.1. Market size and forecast

6.4. Home Healthcare

6.4.1. Market size and forecast

Chapter: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY GEOGRAPHY

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S.
7.2.5. Canada
7.2.6. Mexico

7.3. Europe

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany
7.3.5. France
7.3.6. UK
7.3.7. Spain
7.3.8. Italy
7.3.9. Netherlands
7.3.10. Norway
7.3.11. Sweden
7.3.12. Denmark
7.3.13. Finland
7.3.14. Rest of Europe

7.4. Asia-Pacific

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. India
7.4.5. Australia
7.4.6. China
7.4.7. Japan
7.4.8. South Korea
7.4.9. Rest of Asia-Pacific

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil
7.5.5. Saudi Arabia
7.5.6. South Africa
7.5.7. Venezuela
7.5.8. Argentina
7.5.9. Rest of LAMEA

Chapter: 8 COMPANY PROFILES

8.1. Abbott laboratories

8.1.1. Overview
8.1.2. ABBOTT: company snapshot
8.1.3. Operating business segments
8.1.4. Abbott: operating segments
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Dexcom, inc.

8.2.1. Overview
8.2.2. DexCom: company snapshot
8.2.3. Business performance
8.2.4. Key strategic moves and developments

8.3. Echo Therapeutics, Inc.

8.3.1. Overview
8.3.2. Echo Therapeutics: company snapshot
8.3.3. Business performance
8.3.4. Key strategic moves and developments

8.4. Glysens Incorporated

8.4.1. Overview
8.4.2. GlySens: company snapshot
8.4.3. Key strategic moves and developments

8.5. Insulet Corporation

8.5.1. Overview
8.5.2. Insulet: company snapshot
8.5.3. Business performance
8.5.4. Key strategic moves and developments

8.6. Johnson & Johnson

8.6.1. Overview
8.6.2. JnJ: company snapshot
8.6.3. Operating business segments
8.6.4. JNJ: operating segments
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. Medtronic plc

8.7.1. Overview
8.7.2. Medtronic: company snapshot
8.7.3. Operating business segments
8.7.4. Medtronic: operating segments
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Senseonics Holdings, Inc.

8.8.1. Overview
8.8.2. Senseonics: company snapshot
8.8.3. Key strategic moves and developments

8.9. F. HOFFMANN-LA ROCHE LTD.

8.9.1. Overview
8.9.2. Roche: company snapshot
8.9.3. Business performance
8.9.4. Key strategic moves and developments

The other companies in the CGMS market include:

  • AgaMatrix, Inc.
  • Arkray USA, Inc.
  • Glucovation
  • GlySure
  • OrSense
  • GlySure
  • Pinnacle Technology

*Profiles of these players are not included. The same will be included on request.

LIST OF TABLES

TABLE 1. FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2016)
TABLE 2. FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2016)
TABLE 3. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 4. GLOBAL CONTINUOUS GLUCOSE MONITORING SENSORS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 5. GLOBAL CONTINUOUS GLUCOSE MONITORING TRANSMITTERS AND RECEIVERS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 6. GLOBAL CONTINUOUS GLUCOSE MONITORING INTEGRATED INSULIN PUMPS MARKET, BY REGION, 20142022 ($THOUSAND)
TABLE 7. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 8. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION (>14YEARS), BY REGION, 2014-2022 ($THOUSAND)
TABLE 9. TYPE-1 DIABETES (014 YEARS), 2015
TABLE 10. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET CHILD POPULATION (14YEARS), BY REGION, 2014-2022 ($THOUSAND)
TABLE 11. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 12. DIAGNOSTICS/CLINICS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 13. ICUS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 14. ICUS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 15. TOP FACTORS IMPACTING GLOBAL CGMS MARKET IN 2015 AND 2022, BY GEOGRAPHY
TABLE 16. TOP 10 COUNTRIES WITH DIABETES INCIDENCE (2079 YEARS), 2015 AND 2040
TABLE 17. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 18. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 19. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 20. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 21. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 22. PREVALENCE ESTIMATES OF DIABETES (2079 YEARS) IN EUROPE, 2015
TABLE 23. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 24. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 25. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 26. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 27. MEDICAL DEVICES USED IN AUSTRALIA
TABLE 28. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 29. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 30. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 31. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 32. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 33. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 34. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 35. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 36. ABBOTT: COMPANY SNAPSHOT
TABLE 37. ABBOTT: OPERATING SEGMENTS
TABLE 38. DEXCOM: COMPANY SNAPSHOT
TABLE 39. ECHO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 40. GLYSENS: COMPANY SNAPSHOT
TABLE 41. INSULET: COMPANY SNAPSHOT
TABLE 42. JNJ: COMPANY SNAPSHOT
TABLE 43. JNJ: OPERATING SEGMENTS
TABLE 44. MEDTRONIC: COMPANY SNAPSHOT
TABLE 45. MEDTRONIC: OPERATING SEGMENTS
TABLE 46. SENSEONICS: COMPANY SNAPSHOT
TABLE 47. ROCHE: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. PREVALENCE OF TYPE 1 DIABETES (AGE GROUP OF <15 YEARS), BY GEOGRAPHY (2015)
FIGURE 2. GLOBAL PREVALENCE OF TYPE-2 DIABETES (2014)
FIGURE 3. SIMILAR PREDISPOSITION AND RISK FACTORS FOR PREDIABETES AND TYPE-2 DIABETES
FIGURE 4. TOP TEN COUNTRIES/TERRITORIES FOR DIABETES-RELATED HEALTH EXPENDITURE, 2015
FIGURE 5. GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIGURE 6. OCCURRENCE OF HYPERGLYCEMIA IN ICUS
FIGURE 7. TOP INVESTMENT POCKETS IN CGMS, BY COMPONENTS SEGMENT
FIGURE 8. TOP WINNING STRATEGIES IN CGMS MARKET: PERCENTAGE DISTRIBUTION (20142016)
FIGURE 9. TOP WINNING STRATEGIES IN CGMS MARKET: NATURE AND TYPE (20142016)
FIGURE 10. VALUE CHAIN OF GLOBAL CGMS MARKET
FIGURE 11. PATENTS REGISTERED/APPROVED IN THE WORLD THROUGH 2016
FIGURE 12. PATENT ANALYSIS BY MARKET PARTICIPANT, 20102016
FIGURE 13. U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010 THROUGH 2016
FIGURE 14. PATENTS ANALYSIS BY YEAR, 2010 THROUGH 2016
FIGURE 15. MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET, 2015
FIGURE 16. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 17. TOP IMPACTING FACTORS OF GLOBAL CGMS MARKET, 2015 AND 2022
FIGURE 18. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 19. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 20. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 21. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 22. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 23. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 24. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 25. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 26. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 27. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 28. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 29. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 30. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 31. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 32. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 33. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 34. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 35. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 36. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 37. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 38. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 39. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 40. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 41. VENEZUELA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 42. ARGENTINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 43. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 44. ABBOTT: REVENUE, BY YEAR ($MILLION)
FIGURE 45. ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 46. ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 47. DEXCOM: REVENUE, BY YEAR ($MILLION)
FIGURE 48. DEXCOM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 49. ECHO THERAPEUTICS: REVENUE, BY YEAR ($MILLION)
FIGURE 50. INSULET: REVENUE, BY YEAR ($MILLION)
FIGURE 51. JNJ: REVENUE, BY YEAR ($MILLION)
FIGURE 52. JNJ: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 53. JNJ: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 54. MEDTRONIC: REVENUE, BY YEAR ($MILLION)
FIGURE 55. MEDTRONIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 56. MEDTRONIC: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 57. ROCHE: REVENUE, BY YEAR ($MILLION)
FIGURE 58. ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)

 

The global continuous glucose monitoring systems market is characterized by the ability to manage diabetes by providing real time values of the glucose levels and alerts to the patient in the event of hypo or hyperglycemia. This helps reduce the probability of any complications related to diabetes. In addition, CGMS offers varied benefits over other glucose monitors in monitoring the blood glucose levels of ICU patients. The conventional POC and SMBG devices imparts discomfort or pain in patients. Therefore, CGMS are preferred over SMBG/POC devices. Undiagnosed geriatric patient population will provide attractive market opportunities for integrated CGMS developers. This is due to the fact that the geriatric patients often suffer from multiple and chronic diseases, which require various medications and at much higher frequency intervals, as compared to the other cohorts. In addition, chances to skip or forget the hypoglycemic medications are higher in geriatric patients. CGMS devices automatically deliver the insulin dosage in such patients without any efforts. Due to these reasons, geriatric patients are more amenable to integrated CGMS devices that help maintain tight glycemic control (TGC) and auto-deliver insulin as per the circadian clock.

Due to the growth in demand for advanced CGMS devices, the technology is revolutionized. For instance, smartphone-connected CGMS are the devices that connect with a smartphone’s built-in activity monitor, GPS, scheduling systems, contacts, camera, and voice activation, and sub-sequentially displays results and trend analyses. Non-invasive CGMs such as Symphony CGM System gain importance owing to their user-friendliness, widespread applications, and FDA approvals for these products. Bionic pancreas, a smart and a complete diabetes management solution majorly for Type I diabetes patients aged 14 years and older, was the ultimate objective in terms of technological evolution of the CGMS, which is achieved by Medtronic, Inc. on September 2016.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Global Continuous Glucose Monitoring Systems Market- Global Opportunity Analysis and Industry Forecast, 2014 - 2022

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts